nivolumab,ipilimumab
bms
['prime-hcc', 'nivo', 'hcc']
 asco hcc glad to present the updated results from our neoadjuvant prime-hcc for resectable hcc 25 pts
2 cycles of ici (ipi-nivo, then nivo only) --&gt;surgery mfup 14.5 mos 29% orr,95% dcr 56% major path response (!) tme and microbiota predict for response 
Medical Oncologist and PhD student at Imperial College London.
HCC, immuno-oncology.
Curiosity-driven.